A5046458474- Malaria Research and Control
- Mosquito-borne diseases and control
- Virology and Viral Diseases
- Hepatitis B Virus Studies
- Hepatitis Viruses Studies and Epidemiology
- Respiratory viral infections research
- Virus-based gene therapy research
- Computational Drug Discovery Methods
- Viral Infections and Immunology Research
- Hepatitis C virus research
- Viral gastroenteritis research and epidemiology
- Tuberculosis Research and Epidemiology
- Escherichia coli research studies
- Influenza Virus Research Studies
- vaccines and immunoinformatics approaches
- Viral Infectious Diseases and Gene Expression in Insects
- Health Systems, Economic Evaluations, Quality of Life
- Salmonella and Campylobacter epidemiology
- Research on Leishmaniasis Studies
- Pharmaceutical Economics and Policy
- Diverse Scientific Research Studies
- RNA and protein synthesis mechanisms
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Polyamine Metabolism and Applications
Vienna Vaccine Safety Initiative
2015-2025
Heidelberg University
2011-2024
University Hospital Heidelberg
2011-2024
Novasep (Belgium)
2002-2011
Université Libre de Bruxelles
1989-2000
Malaria in pregnancy has major impacts on mother and child health. To complement existing interventions, such as intermittent preventive treatment use of impregnated bed nets, we developed a malaria vaccine candidate with the aim reducing sequestration asexual "blood-stage" parasites placenta, virulence mechanism.The PAMVAC is based recombinant fragment VAR2CSA, Plasmodium falciparum protein responsible for binding to placenta via chondroitin sulfate A (CSA). Healthy, adult malaria-naive...
The generation of protective humoral immunity after vaccination relies on the productive interaction between antigen-specific B cells and T follicular helper (Tfh) cells. Despite central role Tfh in vaccine responses, there is currently no validated way to enhance their differentiation humans. From paired human lymph node blood samples, we identify a population circulating that are transcriptionally clonally similar germinal center In clinical trial formulations, were expanded Tanzanian...
Shigella infections remain endemic in places with poor sanitation and are a leading cause of diarrheal mortality globally, as well major contributor to gut enteropathy stunting. There currently no licensed vaccines for shigellosis but it has been estimated that an effective vaccine could avert 590,000 deaths over 20-year period. A challenge development the low immunogenicity protective efficacy candidate infants young children. Additionally, new might be less immunogenic highly setting...
The disease caused by Plasmodium falciparum (Pf) involves different clinical manifestations that, cumulatively, kill hundreds of thousands every year. Placental malaria (PM) is one such manifestation in which Pf infected erythrocytes (IE) bind to chondroitin sulphate A (CSA) through expression VAR2CSA, a parasite-derived antigen. Protection against PM mediated antibodies that inhibit binding IE the placental intervillous space. VAR2CSA large antigen incompatible with scale recombinant...
Placental malaria caused by Plasmodium falciparum infection constitutes a major health problem manifesting as severe disease and anaemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. Prevention of placental currently relies on two key strategies that are losing efficacy due to spread resistance: long-lasting insecticide-treated nets intermittent preventive treatment during pregnancy. A vaccine would be an attractive, cost-effective complement existing...
P27A is an unstructured 104mer synthetic peptide from Plasmodium falciparum trophozoite exported protein 1 (TEX1), the target of human antibodies inhibiting parasite growth. The present project aimed at evaluating safety and immunogenicity vaccine in malaria-nonexposed European malaria-exposed African adults.This study was designed as a staggered, fast-track, randomized, antigen adjuvant dose-finding, multicenter phase 1a/1b trial, conducted Switzerland Tanzania. (10 or 50 μg), adjuvanted...
BK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to aluminium hydroxide gel and reconstituted, prior administration, with synthetic oligodeoxynucleotides bearing CpG motifs. In healthy Japanese adult males, was well tolerated. This study assessed its safety immunogenicity in malaria-exposed African adults children.A double-blind, randomised, controlled, age de-escalating clinical trial...
Background A vaccine targeting the erythrocyte stages of Plasmodium falciparum could play a role in preventing clinical disease. BK-SE36 is promising malaria candidate that has shown good safety profile and immunological responses during field evaluations. It was observed repeated natural infections result immune tolerance against SE36 molecule. Methods The primary trial conducted to assess immunogenicity two cohorts children aged 25-60 months (Cohort 1) 12-24 2). Immunization at full dose...
Background A blood-stage vaccine targeting the erythrocytic-stages of malaria parasite Plasmodium falciparum could play a role to protect against clinical disease. Antibodies P. serine repeat antigen 5 (SE47 and SE36 domains) correlate well with absence symptoms in sero-epidemiological studies. previous phase Ib trial recombinant formulated aluminum hydroxyl gel (BK-SE36) was promising. This is first time candidate evaluated young children below years using two vaccination routes. Methods...
ABSTRACT Recombinant hemagglutinin (H) protein of the measles virus (MV) was produced in mammalian cells with a high-yield expression system based on Semliki Forest replicon. Crude membrane preparations H protein-transfected BHK-21 were used to coat microtiter plates measure specific immunoglobulin G antibodies 228 serologically defined serum samples mainly from late-convalescent adults. The titers by enzyme-linked immunosorbent assay for (H-ELISA) closely correlated neutralization test (NT)...
Background: Three doses of the investigational AS02v-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection and higher anti-HBs antibody concentrations in patients with renal insufficiency than four FENDrix™ (HB-AS04), an adjuvanted HBV licensed Europe for use this population. This study evaluated persistence immune response up 36 months after primary vaccination.Methods: In open, international, Phase III follow-up study, 151 pre-dialysis,...
HB-AS02 is an investigational adjuvanted hepatitis B virus (HBV) vaccine for potential use in patients with renal insufficiency and other immunocompromized individuals. In this Phase III lot-to-lot consistency study, 450 healthy adult volunteers who had not previously been vaccinated against HBV were randomized to one of three production lots at 0 1 month followed until after the last dose. Lot-to-lot was established. High seroprotection rates already achieved first dose (75.9%). All...
The fusion (F) and haemagglutinin—neuraminidase (HN) glycoproteins of mumps virus (MuV) have been produced in CV1 cells via vaccinia recombinants. Recombinant proteins accumulated infected were glycosylated. Upon reduction, the F protein product was completely converted into its subunits. Hamsters with recombinants expressing either or HN antibodies recognizing MuV antigens neutralizing infectivity vitro. These provided protection against MuV-induced encephalitis newborn hamsters.
Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is a leading asexual blood stage vaccine candidate for malaria. In preparation clinical trials, three Diversity Covering (DiCo) PfAMA1 ectodomain proteins, designed to overcome the intrinsic polymorphism that present in PfAMA1, were produced under Good Manufacturing Practice (GMP) Pichia pastoris. Using identical methodology, 3 strains cultivated 70-L scale fed-batch fermentations and PfAMA1-DiCos purified by two chromatography steps,...
The estimates of enterotoxigenic Escherichia coli (ETEC) and Shigella burden in developing countries are limited by the lack rapid, accessible, sensitive diagnostics surveillance tools. We used a “Rapid LAMP based Diagnostic Test (RLDT)” to detect ETEC diarrheal non-diarrheal stool samples from 12-month longitudinal cohort children under five years age peri-urban area Ouagadougou Burkina Faso (West Africa). To allow comparison with RLDT-Shigella results, conventional culture methods were...